The deal, facilitated by the Johnson & Johnson Innovation Center, will see Janssen develop and may commercialize the pharmaceutical candidate in inflammatory bowel disease (IBD). As part of
The deal will see evaluation of the safety, tolerability and efficacy of Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials. As part
Enadenotucirev (previously called as ColoAd1) is currently being evaluated in a Phase I/II trial (OCTAVE) in platinum-resistant ovarian cancer patients across multiple UK cancer centres. The Phase I/II
The move follows a deal signed in April 2014, under which Novartis had agreed with GSK to create a global consumer healthcare JV as part of its global
Beta-lactamase inhibitors are designed to restore or potentiate the activity of beta-lactam antibiotics. As part of the deal, Roche secured worldwide rights from both companies to develop and
Under the deal, Colchicine Tablets, USP will be the only colchicine product on the market that is therapeutically equivalent and automatically substitutable for prescriptions written for Colcrys Tablets.
As part of the deal, Mundipharma and Purdue could make payments in excess of $1bn to Esteve if all development, regulatory and sales milestones are met across the
Under the five-year deal, Perrigo will have exclusivity on a full line of store brand gummy vitamin, mineral and supplement products using Ferrara’s gummy technology and manufacturing capabilities.
Alirocumab is an investigational monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). The marketing application is based on data from more than 5,000 patients, including ten Phase
The deal will see development of new treatments using Omnis’ cancer-killing virus technology and later sell them if they seem to be successful. In the project, key agents
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.